- Home
- ONVO vs CERO Comparison
ONVO vs CERO Comparison
Compare ONVO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- CERO
- Stock Information
- Founded
- ONVO 2007
- CERO 2017
- Country
- ONVO United States
- CERO United States
- Employees
- ONVO N/A
- CERO N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- CERO
- Sector
- ONVO Health Care
- CERO
- Exchange
- ONVO Nasdaq
- CERO Nasdaq
- Market Cap
- ONVO 3.0M
- CERO 3.1M
- IPO Year
- ONVO N/A
- CERO N/A
- Fundamental
- Price
- ONVO $1.87
- CERO $0.89
- Analyst Decision
- ONVO
- CERO Strong Buy
- Analyst Count
- ONVO 0
- CERO 1
- Target Price
- ONVO N/A
- CERO $11.00
- AVG Volume (30 Days)
- ONVO 347.1K
- CERO 4.4M
- Earning Date
- ONVO 05-30-2025
- CERO 04-15-2025
- Dividend Yield
- ONVO N/A
- CERO N/A
- EPS Growth
- ONVO N/A
- CERO N/A
- EPS
- ONVO N/A
- CERO N/A
- Revenue
- ONVO $122,000.00
- CERO N/A
- Revenue This Year
- ONVO $59.08
- CERO N/A
- Revenue Next Year
- ONVO $18.24
- CERO N/A
- P/E Ratio
- ONVO N/A
- CERO N/A
- Revenue Growth
- ONVO N/A
- CERO N/A
- 52 Week Low
- ONVO $1.56
- CERO $0.53
- 52 Week High
- ONVO $21.96
- CERO $171.00
- Technical
- Relative Strength Index (RSI)
- ONVO 37.84
- CERO 49.91
- Support Level
- ONVO $1.56
- CERO $0.53
- Resistance Level
- ONVO $1.78
- CERO $1.42
- Average True Range (ATR)
- ONVO 0.24
- CERO 0.12
- MACD
- ONVO 0.13
- CERO 0.07
- Stochastic Oscillator
- ONVO 43.06
- CERO 40.19
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.